MorphoSys Signs Long-Term Alliance with Pfizer on Sloning Technology Platform
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Signs Long-Term Alliance with Pfizer on Sloning Technology Platform
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
signing of a non-exclusive license and technology transfer agreement between its
subsidiary Sloning BioTechnology GmbH and Pfizer. The agreement covers the
installation, training and use of Sloning's technology platform Slonomics® for
fabrication of highly-diverse gene and protein libraries at Pfizer's subsidiary
Rinat Neuroscience Corp. in South San Francisco. The MorphoSys subsidiary will
receive an upfront payment in 2010, and stands to receive annual license fees
over the patent lifetime of the Slonomics technology platform. Further financial
details of the agreement were not disclosed.
"This significant alliance around the Slonomics technology, only weeks after we
closed the acquisition of Sloning, clearly illustrates the potential value of
the platform," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys
AG. "This alliance with Pfizer creates immediate value for our shareholders and
is just the beginning of what we expect to be a considerable return-on-
investment from the combined technology platforms of MorphoSys and Sloning in
the years ahead."
"Rinat started using Sloning's services in 2009, and we were impressed by the
diversity and quality of the libraries delivered," said Jaume Pons, PhD, Chief
Scientific Officer at Pfizer's Rinat subsidiary. "We therefore decided to use
this innovative technology platform further for our research and development
activities."
Sloning's state-of-the-art Slonomics technology enables the precise construction
of protein libraries comprising defined mixtures of amino acids at pre-
determined positions with unprecedented speed. The technology provides a new and
flexible approach to generating optimized proteins. MorphoSys acquired Sloning
BioTechnology in October 2010.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
?
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered
trademarks of MorphoSys AG. Slonomics® is a registered trademark of Sloning
BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
http://hugin.info/130295/R/1471129/407964.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1471129]
Unternehmensinformation / Kurzprofil:
Datum: 10.12.2010 - 07:04 Uhr
Sprache: Deutsch
News-ID 49589
Anzahl Zeichen: 6270
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 370 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Signs Long-Term Alliance with Pfizer on Sloning Technology Platform"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
